Literature DB >> 31610040

Association of Mineral Bone Disorder With Decline in Residual Kidney Function in Incident Hemodialysis Patients.

Yu-Ji Lee1,2, Yusuke Okuda1, John Sy3, Yoshitsugu Obi1, Duk-Hee Kang1,4, Steven Nguyen1, Jui Ting Hsiung1, Christina Park1, Connie M Rhee1, Csaba P Kovesdy5,6, Elani Streja1, Kamyar Kalantar-Zadeh1.   

Abstract

Abnormalities of mineral bone disorder (MBD) parameters have been suggested to be associated with poor renal outcome in predialysis patients. However, the impact of those parameters on decline in residual kidney function (RKF) is uncertain among incident hemodialysis (HD) patients. We performed a retrospective cohort study in 13,772 patients who initiated conventional HD during 2007 to 2011 and survived 6 months of dialysis. We examined the association of baseline serum phosphorus, calcium, intact parathyroid hormone (PTH), and alkaline phosphatase (ALP) with a decline in RKF. Decline in RKF was assessed by estimated slope of renal urea clearance (KRU) over 6 months from HD initiation. Our cohort had a mean ± SD age of 62 ± 15 years; 64% were men, 57% were white, 65% had diabetes, and 51% had hypertension. The median (interquartile range [IQR]) baseline KRU level was 3.4 (2.0, 5.2) mL/min/1.73 m2 . The median (IQR) estimated 6-month KRU slope was -1.47 (-2.24, -0.63) mL/min/1.73 m2 per 6 months. In linear regression models, higher phosphorus categories were associated with a steeper 6-month KRU slope compared with the reference category (phosphorus 4.0 to <4.5 mg/dL). Lower calcium and higher intact PTH and ALP categories were also associated with a steeper 6-month KRU slope compared with their respective reference groups (calcium 9.2 to <9.5 mg/dL; intact PTH 150 to <250 pg/mL; ALP <60 U/L). The increased number of parameter abnormalities had an additive effect on decline in RKF. Abnormalities of MBD parameters including higher phosphorus, intact PTH, ALP and lower calcium levels were independently associated with decline in RKF in incident HD patients.
© 2019 American Society for Bone and Mineral Research. © 2019 American Society for Bone and Mineral Research. © 2019 American Society for Bone and Mineral Research.

Entities:  

Keywords:  ALKALINE PHOSPHATASE; HEMODIALYSIS; PARATHYROID HORMONE; PHOSPHORUS; RESIDUAL KIDNEY FUNCTION

Mesh:

Substances:

Year:  2019        PMID: 31610040     DOI: 10.1002/jbmr.3893

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  4 in total

1.  Comparative Effectiveness of Dialysis Modality on Laboratory Parameters of Mineral Metabolism.

Authors:  Melissa Soohoo; Yoshitsugu Obi; Matthew B Rivara; Scott V Adams; Wei Ling Lau; Connie M Rhee; Csaba P Kovesdy; Kamyar Kalantar-Zadeh; Onyebuchi A Arah; Rajnish Mehrotra; Elani Streja
Journal:  Am J Nephrol       Date:  2022-02-28       Impact factor: 4.605

Review 2.  Parathyroid Hormone: A Uremic Toxin.

Authors:  Eduardo J Duque; Rosilene M Elias; Rosa M A Moysés
Journal:  Toxins (Basel)       Date:  2020-03-17       Impact factor: 4.546

Review 3.  Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease.

Authors:  Markus Ketteler; Patrice Ambühl
Journal:  J Nephrol       Date:  2021-06-25       Impact factor: 3.902

4.  The Protein-Independent Role of Phosphate in the Progression of Chronic Kidney Disease.

Authors:  Irene Faria Duayer; Eduardo Jorge Duque; Clarice Kazue Fujihara; Ivone Braga de Oliveira; Luciene Machado Dos Reis; Flavia Gomes Machado; Fabiana Giorgetti Graciolli; Vanda Jorgetti; Roberto Zatz; Rosilene Motta Elias; Rosa Maria Affonso Moysés
Journal:  Toxins (Basel)       Date:  2021-07-19       Impact factor: 4.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.